Dianthus Therapeutics Files S-1/A Amendment

TL;DR

<b>Dianthus Therapeutics, Inc. has filed an S-1/A amendment detailing corporate history, recent financing activities, and past agreements.</b>

AI Summary

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Amended IPO Registration (S-1/A) with the SEC on March 21, 2024. Dianthus Therapeutics, Inc. filed an S-1/A amendment on March 21, 2024. The company was formerly known as Magenta Therapeutics, Inc., with a name change on November 21, 2016. Key events include a private placement and prefunded warrants on January 22, 2024. The filing references agreements with Zenas Biopharma Limited, including upfront payments and milestones. Various stock and warrant issuances are noted, dating back to 2019.

Why It Matters

For investors and stakeholders tracking Dianthus Therapeutics, Inc. /DE/, this filing contains several important signals. This amendment provides updated information for potential investors regarding the company's structure, financing, and historical transactions. The filing clarifies past relationships and financial arrangements, which are crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — Dianthus Therapeutics, Inc. /DE/ shows moderate risk based on this filing. The filing is an amendment to an S-1 registration statement, indicating ongoing efforts to go public or raise capital, which inherently carries market and execution risks.

Analyst Insight

Monitor future filings for updates on the company's progress towards its stated objectives, particularly regarding financing and clinical development.

Key Numbers

• 2024-03-21 — Filing Date (S-1/A filing date)
• 2016-11-21 — Name Change Date (From Magenta Therapeutics, Inc.)
• 2024-01-22 — Financing Date (Private placement and prefunded warrants)
• 2023-03-15 — Agreement Date (With Zenas Biopharma Limited)

Key Players & Entities

• Dianthus Therapeutics, Inc. (company) — Filer name
• Magenta Therapeutics, Inc. (company) — Former company name
• Zenas Biopharma Limited (company) — Party to agreements
• Fairmount Funds (company) — Mentioned in relation to Zenas Biopharma
• Alloy Therapeutics Llc (company) — Mentioned in context of 2023 activities
• Iontas Limited (company) — Mentioned in context of 2023 activities
• Omniab Inc (company) — Mentioned in context of 2023 activities
• 2024-01-22 (date) — Date of private placement and prefunded warrants

FAQ

Industry Context

Dianthus Therapeutics operates in the pharmaceutical preparations industry, focusing on therapeutic development.

Regulatory Implications

The filing is made under the Securities Act of 1933, governing the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and risk factors.
2. Track subsequent amendments or updates to this registration statement.
3. Research the company's therapeutic pipeline and development stage.

Key Dates

• 2024-03-21: S-1/A Filing — Updated disclosure for potential investors.
• 2024-01-22: Private Placement & Prefunded Warrants — Recent financing activity.
• 2016-11-21: Name Change — Transition from Magenta Therapeutics, Inc.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates and revisions to the initial registration statement.

Key Financial Figures

• $0.001 — 6,988 shares of common stock, par value $0.001 per share (the "Common Stock" and, such
• $27.10 — ed sales price for our Common Stock was $27.10 per share. An investment in our secur

Filing Documents

• d602978ds1a.htm (S-1/A) — 2171KB
• d602978dex51.htm (EX-5.1) — 7KB
• d602978dex231.htm (EX-23.1) — 1KB
• d602978dexfilingfees.htm (EX-FILING FEES) — 38KB
• g602978g0319120406919.jpg (GRAPHIC) — 2KB
• g602978g04g04.jpg (GRAPHIC) — 33KB
• g602978g04g07.jpg (GRAPHIC) — 63KB
• g602978g04g08.jpg (GRAPHIC) — 151KB
• g602978g05g05.jpg (GRAPHIC) — 77KB
• g602978g34g34.jpg (GRAPHIC) — 73KB
• 0001193125-24-073956.txt (&nbsp;) — 9172KB
• dnth-20231231.xsd (EX-101.SCH) — 60KB
• dnth-20231231_cal.xml (EX-101.CAL) — 51KB
• dnth-20231231_def.xml (EX-101.DEF) — 318KB
• dnth-20231231_lab.xml (EX-101.LAB) — 491KB
• dnth-20231231_pre.xml (EX-101.PRE) — 420KB
• d602978ds1a_htm.xml (XML) — 1055KB

RISK FACTORS

RISK FACTORS 9 BUSINESS COMBINATION OF DIANTHUS AND OPCO 49 PRIVATE PLACEMENTS OF SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS 52 MARKET PRICE AND DIVIDEND INFORMATION 54

USE OF PROCEEDS

USE OF PROCEEDS 55

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 56 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 72

BUSINESS

BUSINESS 73 MANAGEMENT 107

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 115

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 123 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 127 SELLING STOCKHOLDERS 132 PLAN OF DISTRIBUTION 138

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 140 LEGAL MATTERS 146 EXPERTS 146 WHERE YOU CAN FIND MORE INFORMATION 146 INDEX TO FINANCIAL STATEMENTS F-1 Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC using a "shelf" registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, offer and sell the securities described in this prospectus in one or more offerings. Information about the Selling Stockholders may change over time. This prospectus provides you with a general description of the shares the Selling Stockholders may offer. Each time the Selling Stockholders sell our shares of Common Stock using this prospectus, to the extent necessary and required by law, we will provide a prospectus supplement that will contain specific information about the terms of that offering, including the number of shares of Common Stock being offered, the manner of distribution, the identity of any underwriters or other counterparties and other specific terms related to the offering. The prospectus supplement may also add, update or change information contained in this prospectus. To the extent that any statement made in a prospectus supplement is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement. You should read this prospectus and any applicable prospectus supplement before making an investment in shares of our Common Stock. See " Where You Can Find More Information " for more information. Neither we nor the Selling Stockholders have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to

Use of Proceeds

Use of Proceeds We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale by the Selling Stockholders of the Common Stock. Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. See the section titled "Use of Proceeds" located elsewhere in this prospectus.

Risk Factors

Risk Factors You should read the section titled " Risk Factors " located elsewhere in this prospectus for a discussion of the risks, uncertainties and other factors to consider carefully before deciding to invest in shares of our Common Stock. Nasdaq Capital Market symbol: Our Common Stock is listed on The Nasdaq Capital Market under the symbol "DNTH." We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-reverse split basis. For additional information concerning the offering, see the section titled " Plan of Distribution ." SUMMARY OF RISK FACTORS We have a limited operating history, have not completed any late-stage clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability; We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts; We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products for sale, have not generated any product revenue and may never generate product revenue or become profitable; 6 Table of Contents We face competition from entities that have developed or may develop programs for the diseases we plan to address with DNTH103 or other product candidates; DNTH103 and our other programs are in early stages of development and may fail

View Full Filing

View this S-1/A filing on SEC EDGAR